Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic Quinolones with Adjuvant Bacillus Calmette-Guérin Instillation for Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol
January 2025
S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China; Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China; Department of Urology, Medical University of Vienna, Austria, Vienna. Electronic address:
Background And Objective: Bacillus Calmette-Guérin (BCG) reduces disease recurrence and progression in intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). BCG-associated adverse events during instillations are common, leading to treatment cessation. Prophylactic use of quinolones in conjunction with BCG instillations is one approach for reducing BCG-associated adverse events.
View Article and Find Full Text PDFComparison of treatments for preventing lower urinary tract symptoms after BCG immunotherapy of bladder tumors : a systematic review and network meta-analysis.
BMC Urol
January 2025
Department of Urology, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.
Background: Bacillus Calmette-Guerin (BCG) immunotherapy is the standard adjuvant treatment for high-risk, non-muscle invasive bladder cancer (NMIBC). However, BCG immunotherapy is commonly accompanied by significant lower urinary tract symptoms (LUTS) including symptoms such as urinary urgency, frequency, dysuria and pelvic pain. These symptoms can undermine treatment adherence and clinical outcomes.
View Article and Find Full Text PDFA triphenylamine-based aggregation-induced emission active fluorescent probe for fluorescent ink, fingerprint powder, and visual detection of salmon freshness.
J Sci Food Agric
January 2025
College of Food Science and Technology, Bohai University; Food Safety Key Lab of Liaoning Province; National & Local Joint Engineering Research Center of Storage, Processing and Safety Control Technology for Fresh Agricultural and Aquatic Products, Jinzhou, China.
Background: Multifunctional fluorescent probes have attracted much attention due to their wide range of applications and high utilization. In this study, a multifunctional fluorescent probe (E)-3-(4-(7-(4-(diphenylamino)phenyl)benzo[c] [1,2,5]thiadiazol-4-yl)phenyl)acrylic acid (TBAC) based on triphenylamine was designed and synthesized.
Results: The TBAC probe provided excellent aggregation-induced emission (AIE) performance and could be used as a fluorescent ink for printing.
BCG-Induced DNA Methylation Changes Improve Coronavirus Disease 2019 Vaccine Immunity Without Decreasing the Risk for Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Open Forum Infect Dis
January 2025
Global Tuberculosis Program, William T. Shearer Center for Immunobiology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Background: The BCG vaccine induces trained immunity, an epigenetic-mediated increase in innate immune responsiveness. Therefore, this clinical trial evaluated if BCG-induced trained immunity could decrease coronavirus disease 2019 (COVID-19)-related frequency or severity.
Methods: A double-blind, placebo-controlled clinical trial of healthcare workers randomized participants to vaccination with BCG TICE or placebo (saline).
Effect of Bacille Calmette-Guérin vaccination on immune responses to SARS-CoV-2 and COVID-19 vaccination.
Clin Transl Immunology
January 2025
Infectious Diseases Group, Infection, Immunity and Global Health Theme Murdoch Children's Research Institute Parkville VIC Australia.
Objectives: Bacille Calmette-Guérin (BCG) vaccination has off-target effects on disease risk for unrelated infections and immune responses to vaccines. This study aimed to determine the immunomodulatory effects of BCG vaccination on immune responses to vaccines against SARS-CoV-2.
Methods: Blood samples, from a subset of 275 SARS-CoV-2-naïve healthcare workers randomised to BCG vaccination (BCG group) or no BCG vaccination (Control group) in the BRACE trial, were collected before and 28 days after the primary course (two doses) of ChAdOx1-S (Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech) vaccination.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!